Schuler Education Foundation - 11 Feb 2020 Form 4 Insider Report for BIOLASE, INC (BIOLQ)

Reporting relationship: 10%+ Owner
Issuer ticker: BIOLQ
Reported as of: 11 Feb 2020
Net transaction value: -$1,841,263
SEC form: 4
Accepted by SEC: 26 May 2023, 13:13:30 UTC
Source filing: View source filing
Reporting owner signature: /s/ Jack W. Schuler, President

Key filing fact

Schuler Education Foundation filed Form 4 for BIOLASE, INC (BIOLQ) on 26 May 2023.

Key facts

This page summarizes Schuler Education Foundation's Form 4 filing for BIOLASE, INC (BIOLQ).
15 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 26 May 2023, 13:13.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: -$1,841,263.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIOL transaction

Common Stock

Purchase

Transaction value: $797,838
Shares: +1,307,931
Change %: +14%
Price: $0.6100^*
Shares after: 10,936,444
Date: 11 Feb 2020
Ownership: Direct
Footnotes: F1

BIOL transaction

Common Stock

Sale

Transaction value: $1,016,207
Shares: -1,847,649
Change %: -17%
Price: $0.5500^*
Shares after: 9,088,795
Date: 08 Jun 2020
Ownership: Direct
Footnotes: F1, F2

BIOL transaction

Common Stock

Sale

Transaction value: $1,154,282
Shares: -2,137,559
Change %: -24%
Price: $0.5400^*
Shares after: 6,951,236
Date: 09 Jun 2020
Ownership: Direct
Footnotes: F1, F3

BIOL transaction

Common Stock

Sale

Transaction value: $953,610
Shares: -1,733,836
Change %: -25%
Price: $0.5500^*
Shares after: 5,217,400
Date: 10 Jun 2020
Ownership: Direct
Footnotes: F1, F4

BIOL transaction

Common Stock

Conversion of derivative security

Transaction value: $1,498,000
Shares: +3,745,000
Change %: +72%
Price: $0.4000^*
Shares after: 8,962,400
Date: 28 Jul 2020
Ownership: Direct
Footnotes: F1

BIOL transaction

Common Stock

Sale

Transaction value: $21,330
Shares: -71,100
Change %: -0.79%
Price: $0.3000
Shares after: 8,891,300
Date: 24 Nov 2020
Ownership: Direct
Footnotes: F1

BIOL transaction

Common Stock

Sale

Transaction value: $58,887
Shares: -203,057
Change %: -2.3%
Price: $0.2900
Shares after: 8,688,243
Date: 25 Nov 2020
Ownership: Direct
Footnotes: F1

BIOL transaction

Common Stock

Sale

Transaction value: $334,500
Shares: -1,115,000
Change %: -13%
Price: $0.3000
Shares after: 7,573,243
Date: 30 Nov 2020
Ownership: Direct
Footnotes: F1

BIOL transaction

Common Stock

Sale

Transaction value: $360,000
Shares: -1,200,000
Change %: -16%
Price: $0.3000
Shares after: 6,373,243
Date: 04 Dec 2020
Ownership: Direct
Footnotes: F1

BIOL transaction

Common Stock

Sale

Transaction value: $25,361
Shares: -90,575
Change %: -1.4%
Price: $0.2800
Shares after: 6,282,668
Date: 16 Dec 2020
Ownership: Direct
Footnotes: F1

BIOL transaction

Common Stock

Sale

Transaction value: $160,348
Shares: -572,671
Change %: -9.1%
Price: $0.2800
Shares after: 5,709,997
Date: 17 Dec 2020
Ownership: Direct
Footnotes: F1

BIOL transaction

Common Stock

Sale

Transaction value: $52,577
Shares: -187,774
Change %: -3.3%
Price: $0.2800
Shares after: 5,522,223
Date: 18 Dec 2020
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BIOL transaction Derivative

Series F Convertible Preferred Stock

Award

Transaction value
Shares: +1,498
Change %
Price
Shares after: 1,498
Date: 22 Jul 2020
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,745,000
Exercise price: $0.4000
Footnotes: F1, F5, F6

BIOL transaction Derivative

Warrants

Award

Transaction value
Shares: +3,745,000
Change %
Price
Shares after: 3,745,000
Date: 22 Jul 2020
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,745,000
Exercise price: $0.4000
Footnotes: F1, F5

BIOL transaction Derivative

Series F Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -1,498
Change %: -100%
Price
Shares after: 0
Date: 28 Jul 2020
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,745,000
Exercise price: $0.4000
Footnotes: F1, F6, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Schuler Education Foundation is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 7 footnotes

Footnote F1

This late filing is due to inadvertent administrative error.

Footnote F2

The sale price reported is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.5399 and $0.5643, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.

Footnote F3

The sale price reported is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.5430 and $0.5601, inclusive.

Footnote F4

The sale price reported is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.5485 and $0.5656, inclusive.

Footnote F5

In connection with a public offering by the Issuer, on July 22, 2020, the Reporting Person acquired (i) 1,498 shares of Series F Convertible Preferred Stock, each of which is convertible into 2,500 shares of Common Stock, for a total of up to 3,745,000 shares of Common Stock, and (ii) 3,745,000 Warrants, each of which is exercisable to purchase one share of Common Stock, for a total of up to 3,745,000 shares of Common Stock, for an aggregate purchase price of $1,500,000.

Footnote F6

Each share of Series F Convertible Preferred Stock is convertible at the Issuer's option at any time on or after July 22, 2021 or at the option of the Reporting Person at any time.

Footnote F7

On July 28, 2020, the Reporting Person converted 1,498 shares of Series F Convertible Preferred Stock into 3,745,000 shares of Common Stock.